Turn Therapeutics Inc (TTRX) 財務

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. The company is headquartered in Westlake Village, California. The company went IPO on 2025-10-08. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.